New tyrosine kinase inhibitors in chronic myeloid leukemia
The deregulated activity of BCR-ABL tyrosine kinase originating from the t(9;22) chromosomal translocation has been shown to be necessary and sufficient for the transformed phenotype of chronic myeloid leukemia (CML) cells. This peculiarity has paved the
G Martinelli +4 more
doaj
NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia. [PDF]
Wang X +12 more
europepmc +1 more source
Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors. [PDF]
Masucci MT +4 more
europepmc +1 more source
Gastrointestinal stromal tumor (GIST) is mainly initialized by mutations in receptor tyrosine kinase genes KIT or PDGFRA. The development of imatinib, a small molecule inhibitor that targets these tyrosine kinase receptors, remarkably improved patient ...
Pinar Akcakaya (18668500)
core +1 more source
Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation. [PDF]
Langabeer SE +3 more
europepmc +1 more source
AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. [PDF]
Gayatri MB +6 more
europepmc +1 more source
Identification of Thiazolo[5,4-b]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance. [PDF]
Nam Y +8 more
europepmc +1 more source
Imatinib Resistance in Chronic Myeloid Leukemia Is Associated with Distinct Metabolic, Oxidative, and Autophagic Adaptations in K562-Derived Cell Sublines. [PDF]
Rachid E +5 more
europepmc +1 more source
Imatinib Resistance and Other Diseases Targeted by Imatinib
This lecture from the iBioSeminars project is presented by Brian Druker of HHMI and the Oregon Health & Science University Cancer Institute. It describes how although the majority of patients with CML respond well to imatinib, a minority of patients ...
Druker, Brian J.
core +1 more source
Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines. [PDF]
Alves R +7 more
europepmc +1 more source

